ARID1A and ovarian clear cell cancer: In the ovarian clear cell carcinoma (OCCC), people discovered that ARID1A WT OCCCs enhanced Th1-type immune responses, cytotoxic T cell responses, and NK cell activation, but ARID1A mutant OCCCs lacked type II and type I IFN signaling pathways [34], but the latent mechanism needs to discover.